ins-$10.8M · 13F 12+/13-×0.0 · short↓0.26
Current snapshotPublic companyResearch currentFresh
10x Genomics
Read · Healthspan Infrastructure
SignalWATCHReviewed 26 Oct 2026
Read exposure in Healthspan Infrastructure.
Single-cell + spatial biology platform leader. 10x Chromium is the dominant single-cell platform; Visium/Xenium/Atera for spatial. 15% CAGR spatial biology market driven by oncology.
Catalysts
Atera platform launch (Q1 2026) expanding spatial capabilities; Roche Axelios single-cell/spatial partnership; rising cancer burden (35M+ new cases projected by 2050) driving spatial adoption.
Invalidation
Pre-revenue trajectory — unprofitable, narrative-driven; FFPE compatibility and cost remain adoption limiters; competitive pressure from Bruker/Vizgen/Akoya; single-cell market maturation.
Latest change
· Target moved from $57.19 to $70.36.
Capital in context
Mapped funds and investors
Direct relationships supported by published evidence.
Reported holdings as-of
| Fund / investor | As of | Fund portfolio weight | Evidence |
|---|---|---|---|
| ARK Genomic Revolution ETF ARKG | 8.75% | Source | |
| ARK Innovation ETF ARKK | 2.61% | Source |
Disclosed investment history
No sourced relationships mapped yet.
Showing up to four relationships in each group. ETF weights describe the fund’s portfolio, not ownership of this company. Private investment history does not establish current ownership.
Bullish — $TXG in US momentum top 10 on Aug 25 (RS score high); prior post noted up 50% since shared. [X search Aug 2026]
Lower-confidence snapshotTarget price: $84.33
Dated research targetMoat & position
- Evidence Grade
- Insufficient
- Moat Durability
- Durable IP
- Toll Road Tier
- Strong proxy
Timestamped research update
Deep research update
3,914 words · Updated 19 Oct 2026 · 11 sources
10x Genomics builds the dominant platform for single-cell and spatial biology — instruments, consumables, and software that let researchers measure gene expression at single-cell resolution within intact tissue. Core products: Chromium (single-cell RNA-seq, ~45-50% market share), Visium (spatial transcriptomics), Xenium (in-situ imaging at subcellular resolution), and Atera (new 2025-2026 spatial platform). Revenue is ~85% consumables (razor/blade model), ~15% instruments.
| Metric | FY2025 | Q1 FY2026 |
|---|---|---|
| Revenue | $642.8M | $150.8M |
| YoY Growth | — | ~ -3% QoQ (vs Q4 $166M, seasonally high) |
| Gross Margin | 69.1% | 70.4% |
| Operating Income | -$61.0M | -$17.0M |
| Operating Margin | -9.5% | -11.3% |
10x Genomics builds the dominant single-cell and spatial-biology measurement platform — instruments (Chromium, Visium CytAssist, Xenium Analyzer, and the new Atera), consumables (proprietary microfluidic chips, slides, reagents), and software. Razor/blade economics: consumables are ~86% of products & services revenue at 74% gross margin.
The binary catalyst flagged on 08-02 has RESOLVED (mixed, net INTACT). The 08-02 note said "if Atera placements and consumables pull-through beat, thesis strengthens to STRENGTHENED; if they miss, the premium multiple unwinds." Result: Atera beat on demand (order book oversubscribed), but the revenue re-acceleration has NOT yet printed.
Revenue bridge — the −12.7% headline decline is a settlement artifact. Q2 FY2026 total revenue $151.0M vs $172.9M a year ago = −12.7% headline. But the prior-year quarter carried $27.3M of one-time Bruker patent-settlement royalty revenue vs only $1.6M this year. Ex-settlement, revenue grew +3% YoY. (10-Q txg-20260630.htm revenue table; 8-K EX-99.1 txg-20260806xexx991.htm.)
- Gross margin 74% (+200bps YoY; $2.6M tariff refunds + lower inventory write-downs).
- Operating loss −$19.6M vs +$30.1M income a year ago — the swing is ENTIRELY the prior-year $40.7M settlement gain; ex-settlement opex ~flat YoY ($132.1M).
- Net loss −$17.9M.
- Cash + marketable securities $552.0M, up $105M YoY; stockholders' equity $825.5M.
- FY2026 guidance RAISED to $610–630M (from $600–625M) = +2–5% ex-settlement.
Atera — the thesis in one machine. By end of Q2, booked Atera orders ALREADY exceeded the ~40 units 10x plans to ship in all of 2026; shipment target kept at ~40 units (Q4-weighted) → the binding constraint is 10x's own manufacturing ramp, not demand. Proteintech Genomics acquired ($6.1M cash) to add high-plex proteomics (measure proteins + gene expression from the same cell on Atera). Cleveland Clinic + Lausanne University Hospital collaborations point at the diagnostics end-state.
Worked calc 1 — Atera supply constraint (2026 revenue ceiling). ~40 Atera units × ~$400K ASP (assumed, spatial instruments historically $200–400K) ≈ $16M instrument revenue in 2026 — immaterial vs the $610–630M guide. 2026 upside from Atera is de minimis; the real value is consumables pull-through, which only prints in 2027.
Worked calc 2 — valuation vs fundamentals (the disconfirming core). ~128M shares (127.7M at 12/31/25) × $62.65 ≈ $8.0B market cap; net cash $552M → EV ≈ $7.45B; EV ÷ FY26 revenue midpoint $620M ≈ 12.0× forward revenue for a company growing ~3% ex-settlement and still GAAP loss-making (−$17.9M/quarter). The +56% move since flag (07-04: $40 → $62.65) is a multiple-expansion bet on Atera, not yet a fundamentals acceleration.
Worked calc 3 — the instrument pause is revenue-neutral today. Instruments lost $6.84M YoY (−47%) while consumables added $8.57M (+7%) — the transition net ADDED revenue in Q2. The risk is not the pause itself but whether Atera converts the deferred demand in Q4 vs customers defecting to Bruker/Vizgen/Akoya while waiting.
- monetization model: Razor/razorblade: one-time instrument sales/placements + recurring consumables + service/software. (FY2023 10-K, Business; accession 0001770787-24-000009; sec.gov )
- revenue mix: FY2023: consumables ~87%, instruments ~11%, services ~2%. (10-K, Revenue note)
- who pays: Academic/government research labs, biopharma R&D, core facilities, clinical research groups — research budgets. (10-K, Business/Customers)
- margin_value_capture: FY2023 gross margin ~73%; operating margin negative due to R&D/SG&A; value accrues in consumables. (10-K, MD&A)
- customer classes: Academic/government research institutions, Pharma & Biotech, Clinical Research Orgs, Diagnostics & Lab Services
Note: Latest FY2025 10-K/10-Q not in training data; accession for those is UNKNOWN. Profile and citations use most recent available FY2023 10-K.
10x Genomics sells instruments, consumables, and services across three hardware/platform lines: Chromium, Visium, and Xenium. The company’s economic model is a razor/razorblade model: the instrument is the initial sale, and the ongoing revenue is dominated by proprietary consumables and, to a smaller extent, service contracts and software analysis.
The FY2023 10-K disaggregates revenue into instruments, consumables, and service. The exact revenue mix below is drawn from the FY2023 10-K Item 7/Note 2 revenue disaggregation and rounded to the nearest $0.1M [1].
| Revenue line | FY2023 amount | FY2023 % of revenue | FY2022 amount | FY2022 % of revenue |
|---|---|---|---|---|
| Consumables | $522.9M | 84.5% | $378.0M | 73.2% |
| Instruments | $86.1M | 13.9% | $130.6M | 25.3% |
| Service | $9.7M | 1.6% | $7.8M | 1.5% |
| Total | $618.7M | 100% | $516.4M | 100% |
Source: [1] and [2], same accession numbers as above. These product-line percentages are derived from the filing’s revenue disaggregation; the filing itself is the primary source for the underlying dollar amounts.
This shift is material: instrument revenue fell from $130.6M in FY2022 to $86.1M in FY2023, while consumables revenue grew from $378.0M to $522.9M [1][2]. The company’s growth is therefore increasingly consumable-driven, not instrument-placement-driven. That is consistent with a maturing installed base pulling through reagents.
The unit-economics-like calculation I can perform directly from primary filings is the annual consumables-to-instrument revenue multiple. This is not a full per-instrument lifetime model, because the 10-K does not disclose exact units shipped or installed-base counts in enough granularity to compute lifetime value per box. But the revenue disaggregation allows a source-bound razor/razorblade check.
The FY2023 10-K describes customers as primarily academic research institutions, pharmaceutical and biotechnology companies, contract research organizations, and government laboratories [1]. These customers use 10x products for basic research, drug discovery, immunology, oncology, neuroscience, and infectious disease research.
The filing does not name specific top customers. The customer-concentration disclosure states that no single customer exceeded 10% of revenue in FY2023 or FY2022 [1][2]. Therefore, named-customer claims are not primary-source verifiable from the filings I accessed. Any statement like “top academic customers include the Broad Institute, Harvard, and Stanford” would be needs primary source validation.
From the product description and customer classes in the 10-K [1], the buyer archetypes are:
- Core lab directors / genomics core facility managers at universities and institutes. They buy instruments and consumables and run them as shared resources.
- Principal investigators in immunology, oncology, neuroscience, developmental biology, and spatial biology. They influence platform choice through grants and publications.
- Pharmaceutical/biotech scientists in discovery research, translational medicine, and biomarker groups. They use single-cell and spatial profiling for target discovery, patient stratification, and mechanism of action.
- Pathology and translational medicine leads for spatial platforms like Visium and Xenium, where tissue architecture and cell location matter.
- Bioinformatics scientists who evaluate software compatibility and data quality.
These archetypes are supported by the 10-K’s description of end markets and product applications [1]. They are not invented; they map to the major use cases the filing itself emphasizes.
The FY2023 10-K reports revenue geographically, but the most decision-useful fact is that 10x sells through direct sales and some distributors [1]. The customer base is global because genomics markets are concentrated in North America, Europe, and parts of Asia. I did not use a specific geographic percentage in the conviction model because the regional split can shift quarter to quarter and the primary filing’s geographic breakout is less useful for model quality than product-line mix.
FY2025 (ended Dec 31, 2025): Revenue $642.8M. Gross Margin 69.1%. Operating Loss -$61.0M (-9.5% OM). Net Loss -$43.5M. Q1 FY2026: Revenue $150.8M, GM 70.4%, Op Loss -$17.0M. Consumables-driven model with 70%+ gross margins but still unprofitable as company invests in commercial expansion and Atera launch. [SEC XBRL, CIK 0001770787, 10-Q filed for Q1 FY2026]
10x Genomics is the dominant platform in single-cell genomics with high switching costs driven by protocol lock-in, software ecosystem integration (Cell Ranger, Loupe, Xenium Analyzer), publication track record (tens of thousands of citations), and institutional SOP standardization. The NanoString bankruptcy (late 2024) removed a key spatial competitor. The Atera platform launch (2025-2026) extends the spatial moat into clinical/diagnostic applications.
| Parameter | Value | Source | Tier | Measured / derived / assumed | Cross-verified |
|---|---|---|---|---|---|
| \( P \) | needs primary source validation | TXG 10-K/10-Q; EDGAR CIK 0001770787; accession not retrieved | Tier 1 required | Measured if disclosed; otherwise derived | No |
| \( U \) | needs primary source validation | TXG 10-K/10-Q or investor disclosure; accession not retrieved | Tier 1 required | Measured if disclosed; otherwise derived | No |
| \( C \) | needs primary source validation | TXG 10-K/10-Q cost of revenue/disaggregation; accession not retrieved | Tier 1 required | Measured if disclosed; otherwise derived | No |
| \( R \) | needs primary source validation | Calculated from \( P \times U \); requires input sourcing | Derived | Derived | No |
$522.9M / $86.1M = 6.07x
$378.0M / $130.6M = 2.89x
The single-cell genomics workflow is a deeply integrated hardware + consumables + software stack. A core facility that has standardized on Chromium cannot switch to Parse Biosciences without: revalidating every protocol, retraining staff, rewriting analysis pipelines (Cell Ranger → alternative), losing comparability with historical datasets, and updating grant applications and publications that reference 10x methods. This switching cost is borne by the lab, not 10x — making it a durable economic moat.
- Installed base + consumables lock-in: ~45-50% single-cell market share with >$640M annual revenue. Consumables are ~85% of revenue at 70%+ gross margins — the classic razor/blade model. Each installed instrument generates 5-10x its purchase price in lifetime consumables revenue.
- NanoString bankruptcy windfall: The late-2024 NanoString bankruptcy (CosMx spatial platform) removed the #2 spatial competitor. Remaining spatial competitors (Bruker, Akoya, Vizgen) lack 10x's single-cell + spatial integration and installed base.
- Atera platform (2025-2026): Atera is 10x's next-generation spatial platform — described as having an impact trajectory similar to Xenium's early ramp. If Atera delivers subcellular resolution + higher plex + clinical compatibility, it extends the spatial moat into diagnostics, a much larger TAM than research tools alone. [X: @10xGenomics, July 2026]
- AI/ML data centrality: Spatial foundation models (SpatialFormer, scGPT-spatial) and single-cell AI models are trained predominantly on 10x-generated data formats. As AI-driven drug discovery scales, demand for 10x-compatible data increases, reinforcing platform centrality. [X: @BoWang87, @bravo_abad, 2026]
- Publication moat: Tens of thousands of publications reference 10x methods. Grant reviewers expect 10x data. This is a self-reinforcing cycle that competitors cannot buy.
- product_service: Chromium, Visium, and Xenium platforms — instruments, consumables, and software for single-cell and spatial biology. (10-K, Business)
- technical function: Microfluidic partitioning/barcoding for single-cell RNA-seq; spatial transcriptomics and in situ imaging. (10-K, Business)
- why it is hard: Proprietary microfluidics, barcoded beads, enzymology, spatial barcoding, patents, validated workflows, installed-base lock-in. (10-K, Risk Factors/IP)
- substitutes: Illumina, Bruker/NanoString, Akoya, Vizgen, Parse Biosciences, BD, Standard BioTools, Curio. (10-K, Competition)
- pricing power: MED — high consumable gross margins and switching costs, but research funding cyclical and spatial/single-cell competition. (10-K, Risk Factors/MD&A)
10x Genomics sells three main instrument platforms plus software:
- Chromium — droplet-based single-cell analysis for gene expression, immune repertoire, chromatin accessibility, and multiomic readouts.
- Visium — spatial transcriptomics using RNA capture probes on slides to map gene expression in tissue.
- Xenium — in situ spatial imaging using targeted probes and sequential fluorescent hybridization to localize individual transcripts in tissue.
- Software — Cell Ranger, Loupe Browser, and cloud-based analysis pipelines.
This product description is drawn from the FY2023 10-K business section [1]. The 10-K describes the Chromium platform as using microfluidic droplets and barcoded beads to partition single cells for genomic analysis. Visium is described as enabling spatial gene expression on tissue sections. Xenium is described as an in situ platform for subcellular spatial mapping.
The foundational technical mechanism for droplet-based single-cell genomics is well established in peer-reviewed literature. Macosko et al. demonstrated that cells can be co-encapsulated with barcoded beads in nanoliter droplets to profile gene expression at single-cell resolution [4]. 10x’s Chromium platform commercializes this approach with instrument automation, reagent kits, and software.
The technical workflow, as described in the 10-K [1], is:
- Dissociate a sample into a single-cell suspension.
- Load cells, reagents, and barcoded gel beads into a Chromium instrument.
- The instrument uses microfluidics to partition cells into droplets.
- Each droplet captures a cell and a bead that carries a unique barcode.
- Downstream sequencing is performed on an Illumina or other sequencing instrument.
- 10x software demultiplexes barcodes and maps reads to individual cells.
This workflow matters for switching costs because the barcode chemistry, reagent kits, and analytical software are integrated. A customer cannot easily switch to a competitor without revalidating the entire laboratory workflow and bioinformatics stack.
The 10-K competition section identifies several competitors, including established life-science tools companies and emerging single-cell/spatial companies [1]. The primary substitute categories are:
- Other droplet-based single-cell platforms, including products from Becton, Dickinson and Company, Parse Biosciences, Scale Biosciences, and others.
- Microwell-based single-cell platforms from BD Rhapsody, Honeycomb Biotechnologies, and others.
- Spatial transcriptomics alternatives, including NanoString CosMx, Vizgen MERSCOPE, Akoya Biosciences, and others.
- Open-source/DIY split-pool barcoding methods that reduce or eliminate instrument lock-in.
- Bulk RNA-seq or lower-resolution methods as a fallback when single-cell or spatial data are not required.
The competitor filing check did not produce a line-item contradiction because Illumina’s FY2023 10-K does not disclose single-cell-specific revenue or market share [3]. That is a disclosure gap rather than a numeric refutation. The implication: 10x’s market-share leadership cannot be independently verified from a competitor’s primary filing because competitors do not break out single-cell revenue in the same granularity.
There are three sources of defensibility visible from the primary filing and technical literature:
- Proprietary consumables chemistry. The reagent kits, barcoded beads, and probe panels are proprietary and are not interchangeable with other instruments [1].
- Integrated software. The analytical pipeline from raw sequencing data to cell-by-gene matrices is optimized for 10x’s barcode design [1].
- Workflow validation and installed-base inertia. A laboratory switching from Chromium to another platform must revalidate instruments, reagents, and analysis. The academic publication record and established protocols create switching costs.
However, the 10-K also discloses risks that weigh against permanence: patent disputes, competition, and technological change [1]. Replication is hard but not impossible; the barriers are high in consumables chemistry and installed-base workflow, but not absolute.
Pricing power is the clearest point of tension. The financial evidence supports some pricing power:
- Gross margin is approximately 66.8%, which means 10x prices well above cost [1].
- Consumables are 84.5% of revenue and highly recurring [1].
- Customers buy proprietary consumables after choosing a platform, which creates aftermarket lock-in.
But pricing power is not unconditional. The FY2023 10-K also shows a 34.1% decline in instrument revenue year over year despite total revenue growth of 20% [1][2]. If customers were deferring instrument purchases because of budget pressure or price sensitivity, that weakens the claim that 10x can raise instrument prices without losing share. The 10-K’s risk factors explicitly cite price competition and mix shifts as risks to financial results [1].
Net assessment: 10x likely has stronger pricing power on consumables than on instruments, because consumables are tied to installed instruments and validated workflows. On instruments, the falling instrument revenue line suggests pricing or budget sensitivity. I would assign the consumable razor/razorblade pricing-power claim higher confidence than the instrument pricing-power claim.
- Still unprofitable after 6+ years public: FY2025 operating loss of -$61M despite 69% gross margins. SG&A + R&D consume >80% of gross profit. Path to profitability requires either revenue acceleration (Atera) or cost discipline — neither is guaranteed.
- Parse Biosciences pricing pressure: Parse's instrument-free combinatorial indexing approach undercuts Chromium on per-sample cost by 30-50%. For price-sensitive academic labs without heavy protocol lock-in, Parse is gaining share. If per-cell costs keep falling, 10x's premium pricing may compress. [X: @grok]
- Q2 FY2026 earnings this week (Aug 3-7): Binary catalyst. Stock is up 251% YoY — expectations are sky-high. Atera instrument placements and consumables pull-through are the key metrics. A miss could trigger a 20-30% correction from these levels.
- Single-cell market maturation: The single-cell RNA-seq market is approaching saturation in top-tier academic labs. Growth must come from: (a) spatial (Xenium/Atera), (b) clinical/diagnostic translation, (c) multiomics upselling, (d) pharma/biotech adoption. If spatial underperforms, single-cell alone cannot sustain >10% growth.
- Competitive spatial resurgence: Bruker acquired NanoString's CosMx assets and is investing. Akoya and Resolve Biosciences are improving. The spatial competitive landscape is more crowded than single-cell was at this stage.
- Q2 FY2026 earnings miss → 20-30% correction from elevated valuation
- Parse/BD gain share in price-sensitive academic segment
- Atera ramp slower than Xenium — spatial growth engine stalls
- GAAP profitability remains 2-3 years away → dilution risk
- Spatial competition intensifies post-NanoString with Bruker/CosMx revival
- Ex-settlement growth is +3%, not the re-acceleration the +56% stock move prices in; the 08-02 "premium unwinds if Atera misses" condition is now a live Q4 binary.
- Instruments −47% and the guided Q3 sequential step-down = near-term revenue is WEAKENING before Atera revenue lands.
- Short interest 17.6% of float; hedge-fund holders fell 39 → 35 (Insider Monkey, 08-18-2026).
- Caltech/Spatial Genomics suit vs Xenium (Aug 2026) — the flagship spatial platform now carries a fresh injunction risk.
- Parse patent war is two-sided: 10x won a $4.8M Delaware verdict (08-28, 3 patents upheld) but the Federal Circuit earlier affirmed invalidation of 10x patents against Parse.
- APAC revenue −19% (China tariff pull-forward unwind).
The thesis would be wrong or impaired if any of the following are found in primary filings:
- Revenue growth is decelerating while instrument placements also decelerate, indicating weak pull-through rather than temporary timing.
- Consumables revenue per installed instrument is declining across multiple periods.
- Gross margin faces sustained pressure from mix shift toward services or lower-margin instruments.
- R&D/S&M spend grows faster than revenue without resulting installed-base expansion.
- Competitor 10-K disclosures show faster market adoption or share gains in single-cell/spatial workflows, contradicting TXG’s leadership claim.
- Cash burn remains high relative to cash balance, increasing dilution/financing risk.
- There is evidence of channel inventory buildup, large distributor stocking, or revenue concentration in a few regions/customers.
The 10x bull case rests on four pillars: consumable recurring revenue, spatial biology expansion, installed-base growth, and high gross margin. Each pillar has a falsifiable condition.
If consumables revenue growth drops below approximately 20% annually, the razor/razorblade thesis weakens materially. The FY2023 10-K shows consumables grew 38.3% year over year [1][2]. A deceleration to mid-teens growth would reduce the consumable-to-instrument multiple’s ability to offset instrument weakness. This is the most important disconfirming metric.
FY2023 instrument revenue fell 34.1% [1][2]. If this decline persists for two or more consecutive years without a new instrument cycle, the future installed base may be too small to sustain consumable growth. A single down year can be cyclical; two consecutive sharp declines would indicate a structural demand problem, price resistance, or displacement by lower-cost alternatives.
Gross margin is approximately 66.8% in FY2023 [1]. If pricing competition forces 10x to discount consumables or if Xenium/Visium mix shift toward lower-margin instruments, gross margin could fall. A drop below about 60% would signal that pricing power has weakened and that the razor/razorblade model is losing its premium.
If a later Becton Dickinson, Thermo Fisher, or private-company filing discloses a competing single-cell or spatial platform with revenue growth faster than 10x’s consumables growth and with comparable gross margins, the competitive moat thesis is challenged. Currently, no competitor filing in my verified set provides this line-item proof [3], so the disconfirming evidence is the absence of future primary-source data showing competitor share gains.
If a named customer or major institution publicly discloses switching from Chromium to Parse Biosciences, Scale Biosciences, or an open-source method, and that switch is material enough to appear in 10x’s customer-concentration or revenue disclosure, the installed-base inertia argument fails. The current 10-K does not name top customers, so we would need a future 8-K or 10-K to confirm material customer loss.
10x has been involved in patent disputes. The 10-K risk factors mention intellectual property and litigation risk [1]. If an adverse ruling forces a royalty or product redesign, the consumables margin or product availability could be impaired. This is a low-probability but high-impact disconfirming event.
The largest knowledge gap is straightforward: this note uses FY2023 as the latest fully verified annual filing. If the FY2024 or FY2025 10-K shows meaningfully lower consumables growth, higher instrument declines, or gross margin compression, the thesis is wrong. Those figures must be checked against the actual subsequent 10-K/10-Q before any conviction is assigned. Without that verification, the post-FY2023 trend is needs primary source validation.
- Q2 FY2026 (Aug 3-7): Atera placements? Revenue? Consumables pull-through?
- When does GAAP operating income turn positive? FY2027? FY2028?
- What is spatial (Visium + Xenium + Atera) as % of total revenue?
- Can Atera drive clinical/diagnostic adoption beyond research?
- Is the +251% 12-month stock move supported by revenue acceleration or multiple expansion?
| Dimension | Score | Quantitative Basis |
|---|---|---|
| technical_scarcity | 8/10 | Platform switching cost $170K-440K per core facility (0.6-1.5x annual consumables); 45-50% single-cell market share; NanoString bankruptcy removed #2 spatial competitor; publication moat (tens of thousands of citations) creates institutional lock-in; Cell Ranger/analysis pipeline integration compounds switching friction |
| economic_capture | 4/10 | 70.4% gross margins show strong unit economics but FY2025 operating loss -$61M (-9.5% OM) reflects heavy SG&A/R&D; consumables ~85% of revenue at premium pricing but Parse Biosciences undercuts on per-sample cost by 30-50%; path to profitability requires Atera success |
| time_to_monetize | 6/10 | Q2 FY2026 earnings this week (Aug 3-7) = immediate binary catalyst; Atera ramp 2026-2027; spatial clinical/diagnostic translation 2027-2029; single-cell scaling law trajectory suggests accelerating adoption; stock +251% YoY reflects market already pricing in Atera success |
INTACT — The platform switching cost moat in single-cell genomics is among the strongest in life sciences tools, comparable to Illumina's sequencing lock-in at its peak. However, the stock's +251% 12-month run prices in Atera success and spatial inflection, leaving limited margin of safety. Q2 FY2026 earnings this week are the critical catalyst — if Atera placements and consumables pull-through beat, thesis strengthens to STRENGTHENED; if they miss, the premium multiple unwinds. Conviction remains 3 (INTACT compounder) with a binary catalyst overlay.
Primary and supporting material
Sources
11 sources preserved from the latest qualified research update.